Phio Pharmaceuticals Corp. (PHIO) vs VistaGen Therapeutics, Inc. (VTGN)
A side-by-side comparison of Phio Pharmaceuticals Corp. and VistaGen Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PHIO
Phio Pharmaceuticals Corp.
$0.98HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
VTGN
VistaGen Therapeutics, Inc.
$0.25HealthcareDelayed quote: Oct 6, 2026, 3:54 PM EDT
Total return — PHIO vs VTGN
growth of $100 · dividends reinvested · last 10yPHIO -100.0% (-68.7%/yr)VTGN -99.8% (-46.3%/yr)VTGN compounded faster over this window
Log scale — wide-divergence pair
PHIO VTGN
PHIO vs VTGN: by the numbers
- •PHIO is the larger company ($11M vs $11M market cap).
- •Both run net losses; PHIO's is the smaller (0.00% vs -2702.64% net margin).
Metrics side by side
Valuation
| Metric | PHIO | VTGN |
|---|---|---|
| P/S ratio | N/A | 4.47 |
| P/B ratio | 0.90 | 0.46 |
Profitability
| Metric | PHIO | VTGN |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -5683.69% |
| Net margin | 0.00% | -2702.64% |
| ROE | -102.40% | -276.21% |
| ROIC | -100.51% | -275.74% |
Growth (annualized)
| Metric | PHIO | VTGN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 11.63% |
| Total return CAGR (5Y) | -65.73% | -68.35% |
Frequently asked
- How have PHIO and VTGN total returns compared?
- Over the past 10 years, PHIO delivered -68.44% and VTGN delivered -46.28% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.